ArticleJournal of clinical laboratory analysis2020
MicroRNA-148a-3p inhibits cancer progression and is a novel screening biomarker for gastric cancer.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer.Frontiers in oncology · 2026Article
- A study of microRNAs as new prognostic biomarkers in anal cancer patients.Acta oncologica (Stockholm, Sweden) · 2024Article
- Non-Coding RNA as Biomarkers and Their Role in the Pathogenesis of Gastric Cancer-A Narrative Review.International journal of molecular sciences · 2024Review
- Therapeutic potential of miRNAs in placental extracellular vesicles in ovarian and endometrial cancer.Human cell · 2024Article
- Article
- MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients.Frontiers in oncology · 2023Article
- Differential regulatory roles of microRNAs during intramuscular adipogenesis in Chinese Guizhou Congjiang Xiang pigs.Epigenetics · 2022Article
- Review
- Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects.Biomedicines · 2022Review
- miR-148a promotes cell sensitivity through downregulating SOS2 in radiation-resistant non-small cell lung cancer cells.Oncology letters · 2022Article
- Ceramide-mediated gut dysbiosis enhances cholesterol esterification and promotes colorectal tumorigenesis in mice.JCI insight · 2022Article
- Hsa_circ_0046523 Mediates an Immunosuppressive Tumor Microenvironment by Regulating MiR-148a-3p/PD-L1 Axis in Pancreatic Cancer.Frontiers in oncology · 2022Article
- miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway.Journal of clinical laboratory analysis · 2021Article
- MicroRNA-1269b inhibits gastric cancer development through regulating methyltransferase-like 3 (METTL3).Bioengineered · 2021Article
- Metal-Regulatory Transcription Factor-1 Targeted by miR-148a-3p Is Implicated in Human Hepatocellular Carcinoma Progression.Frontiers in oncology · 2021Article
- MicroRNA-148a-3p inhibits cancer progression and is a novel screening biomarker for gastric cancer.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeDysregulation of miR-148a-3p in gastric cancer was reported. However, the diagnostic potential and biological function of miR-148a-3p in gastric cancer progression is not fully studied.
methodsBioinformatics analysis and RT-qPCR assay were performed to analyze the expression of miR-148a-3p in gastric cancer tissues and plasma of gastric cancer patients. Receiver operating characteristic curve analysis was performed to analyze the diagnostic value of miR-148a-3p. In vitro proliferation, apoptosis, migration, invasion, sphere formation assay and Western blotting assay were performed to evaluate the biological function of miR-148a-3p in gastric cancer progression.
resultsmiR-148a-3p was significantly down-regulated in both gastric cancer patients' tissue and plasma samples. Plasma miR-148a-3p showed promising efficacy for gastric cancer diagnosis. Overexpression of miR-148a-3p could inhibit the proliferative phenotype, metastatic phenotype, and cancer stem-like properties of gastric cancer cells.
conclusionsmiR-148a-3p inhibits cancer progression and is a novel diagnostic biomarker for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.